Skip to main content
SpringerLink
Log in

The effect of two new glucosidase inhibitors on blood glucose in healthy volunteers and in type II diabetics

  • Original Contributions
  • Published:
Acta diabetologia latina Aims and scope Submit manuscript

Summary

Two new glucosidase inhibitors (BAY m 1099 and BAY o 1248) were studied in volunteers and type II diabetics under various conditions. In 6 non-diabetic controls BAY m 1099 when given 3×50 mg/day caused a marked depression of the post-meal glucose rise. The effect was found to be more marked after breakfast than after lunch or after dinner. In type II diabetics BAY m 1099, when given in a dose of 2×25 mg/day over one week, had no significant effect on post-meal glucose or serum insulin levels. BAY o 1248, when given as a single dose of 15 mg in the morning to type II diabetics, induced a significant decrease of post-meal glucose rise (35 mg/dl after breakfast, 25 mg/dl after lunch) when compared to placebo. Although in parallel serum insulin levels were slightly lower, this change was statistically not significant. The drug reduced glycosuria by 50%. Both compounds induced side effects, such as flatulence or diarrhea when given in therapeutically effective amounts, but were tolerable in most cases. On a weight basis BAY o 1248 was found to have greater therapeutic effects than BAY m 1099. Both drugs can be recommended for use in unsatisfactorily controlled type II diabetics. Further studies should concentrate on the critical dosage which may strike a satisfactory balance between effects and side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cauderay M., Tappy, L., Temler, E., Jéquier E., Hillebrand, I., Felber J. P.: Effect of alpha-glycohydrolase inhibitors (BAY m 1099 and BAY o 1248) on sucrose metabolism in normal men. Metabolism35, 472–477, 1985.

    Article  Google Scholar 

  2. Dimitriadis G., Raptis S., Raptis A., Hatziagelaki E., Mitrakou A., Halvatsiotis P., Ladas S., Hillebrand I.: Effects of two new alpha-glucosidase inhibitors on glycemic control in patients with insulin-dependent diabetes mellitus. Klin. Wschr.64, 405–410, 1986.

    Article  PubMed  CAS  Google Scholar 

  3. Hillebrand I.: Personal communication, 1986.

  4. Hillebrand, I., Boehme K., Graefe K. H., Wehling K.: The effect of new alpha-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man. Klin. Wschr.64, 393–396, 1986.

    Article  PubMed  CAS  Google Scholar 

  5. Joubert P. H., Bam W. J., Manyane N.: Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics. Europ. J. clin. Pharmacol.30, 253–255, 1986.

    Article  CAS  Google Scholar 

  6. Joubert P. H., Venter, C. P., Joubert H. F., Hillebrand I.: The effect of a 1-desoxynojirimycin derivative on post-prandial blood glucose and insulin levels in healthy black and white volunteers. Europ. J. clin. Pharmacol.28, 705–708, 1985.

    Article  CAS  Google Scholar 

  7. Katsilambros N., Philippides Ph., Toskas A., Protopapas J., Frangakis M., Marangos M., Siskouids P., Anastasopoulou K., Xefteri H., Hillebrand I.: A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics. Arzneimittel-Forsch.36, 1136–1138, 1986.

    CAS  Google Scholar 

  8. Puls W., Krause H. P., Müller L., Schutt H., Sitt R., Thomas G.: Inhibitors of the rate of carbohydrate and lipid absorption by the intestine. Int. J. Obesity8 (Suppl. 1), 181–190, 1984.

    CAS  Google Scholar 

  9. Schmidt D. D., Frommer W., Müller, L., Wingender W., Truscheit E., Schäfer D.: Alpha-glucosidase inhibitors. New complex oligosaccharides of microbial origin. Naturwissenschaften64, 535–536, 1977.

    Article  PubMed  CAS  Google Scholar 

  10. Schnack C., Röggly A., Luger A., Schernthaner G.: Effect of the alpha-glucosidase inhibitor 1-desoxynojirimycin (BAY m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients. Europ. J. clin. Pharmacol.30, 417–419, 1986.

    Article  CAS  Google Scholar 

  11. Taylor R. H., Barker H. M., Bowey E. A., Canfield J. E.: Intestinal monosaccharide tran-sport is unimpaired by desoxynojirimycin-derived glycosidase inhibitors. Clin. Sci.67 (Suppl. 9), 63, 1984.

    Google Scholar 

  12. Truscheit E., Frommer W., Junge B., Müller L., Schmidt D. D., Wingender W.: Chemie und Biochemie mikrobieller alpha-glucosidase-Inhibitoren. Angew. Chem.93, 738–755, 1981.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. III. Medizinische Klinik und Poliklinik, Zentrum für Innere Medizin, Universität Giessen, Giessen, FRG

    Konrad F. Federlin, Ludwig Mehlburger, Ingrid Hillebrand & Heinrich Laube

Authors
  1. Konrad F. Federlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ludwig Mehlburger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ingrid Hillebrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Heinrich Laube
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Federlin, K.F., Mehlburger, L., Hillebrand, I. et al. The effect of two new glucosidase inhibitors on blood glucose in healthy volunteers and in type II diabetics. Acta diabet. lat 24, 213–221 (1987). https://doi.org/10.1007/BF02732040

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02732040

Key-words

Search

Navigation